The global weight loss treatment landscape has taken a major leap forward with the launch of Orforglipron, a groundbreaking daily pill developed by Eli Lilly and Company. Marketed under the brand name Foundayo, this innovative drug introduces a long-awaited alternative to injectable weight loss treatments, offering a more convenient and accessible solution for millions of people struggling with obesity. Approved by the U.S. Food and Drug Administration in April 2026, Orforglipron is a once-daily oral medication designed to help adults
